Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69(5):363–385

Article  PubMed  Google Scholar 

Lin S, Chen W, Chen Z, Liang J, Zhong L, Jiang M (2022) Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report. Ann Transl Med 10(6):380

Article  PubMed  PubMed Central  Google Scholar 

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA et al (2017) Effect of First-Line Chemotherapy Combined with Cetuximab or Bevacizumab on overall survival in patients with KRAS Wild-Type Advanced or metastatic colorectal Cancer: a Randomized Clinical Trial. JAMA 317(23):2392–2401

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919

Article  PubMed  Google Scholar 

Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F et al (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32(6):2319–2326

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nukatsuka M, Nakagawa F, Saito H, Sakata M, Uchida J, Takechi T (2015) Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res 35(3):1437–1445

CAS  PubMed  Google Scholar 

Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H et al (2015) Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 33(5):2135–2142

CAS  PubMed  PubMed Central  Google Scholar 

Temmink OH, Hoebe EK, Fukushima M, Peters GJ (2007) Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer 43(1):175–183

Article  CAS  PubMed  Google Scholar 

Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13(4):545–549

CAS  PubMed  Google Scholar 

Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M (2004) A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25(3):571–578

CAS  PubMed  Google Scholar 

van der Velden DL, Opdam FL, Voest EE (2016) TAS-102 for treatment of Advanced Colorectal cancers that are no longer responding to other therapies. Clin Cancer Res 22(12):2835–2839

Article  PubMed  Google Scholar 

Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E et al (2023) Trifluridine-tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med 388(18):1657–1667

Article  CAS  PubMed  Google Scholar 

Varghese AM, Cardin DB, Hersch J, Benson AB, Hochster HS, Makris L et al (2020) Phase I study of Trifluridine/Tipiracil plus irinotecan and Bevacizumab in Advanced gastrointestinal tumors. Clin Cancer Res 26(7):1555–1562

Article  CAS  PubMed  Google Scholar 

Taniguchi H, Yamazaki K, Masuishi T, Kawakami T, Onozawa Y, Honda K et al (2023) Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for metastatic colorectal Cancer: MODURATE, a phase ib study. Oncologist 28(11):e1108–e13

Article  PubMed  PubMed Central  Google Scholar 

Doi T, Yoshino T, Fuse N, Boku N, Yamazaki K, Koizumi W et al (2015) Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Invest New Drugs 33(5):1068–1077

Article  CAS  PubMed  PubMed Central  Google Scholar 

Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H et al (2020) Phase Ib/II study of Biweekly TAS-102 in combination with Bevacizumab for patients with metastatic colorectal Cancer refractory to standard therapies (BiTS study). Oncologist 25(12):e1855–e63

Article  CAS  PubMed  Google Scholar 

Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13(10):993–1001

Article  CAS  PubMed  Google Scholar 

Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853–860

Article  CAS  PubMed  Google Scholar 

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499–3506

Article  PubMed  Google Scholar 

Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A et al (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107(3):429–434

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H et al (2023) Trifluridine/tipiracil + bevacizumab (BEV) vs. fluoropyrimidine-irinotecan + BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. Br J Cancer 128(10):1897–1905

Article  CAS  PubMed  PubMed Central  Google Scholar